The effect of cyclosporine-a on the renal vascular response to ANG II and adrenegic agonist in sprague-dawley rat

HealthMED

Volumn 5, Issue 6 SUPPL. 1, 2011, Pages 1857-1867

  Chia, Tan Yong ^a   Sattar, Munavvar A ^a   Abdulla, Mohammed H ^a   Johns, Edward J ^b  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

1 adrenoceptor; Cyclosporine a; Noradrenaline; Renal failure; Sprague dawley rats

Indexed keywords

EID: 84858120949     PISSN: 18402291     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Satyanarayana PS, Chopra K. Oxidative stress-mediated renal dysfunction by cyclosporine A in rats: attenuation by trimetazidine. Ren Fail 2002; 24:259-274.
2. Andoh TF, Bennett WM. Chronic cyclosporine nep-hrotoxicity. Curr Opin Nephrol Hypertens 1998; 7:265-270.
3. Taler SJ, Textor SC, Canzanello VJ, Schwartz L. Cyc-losporin-induced hypertension: incidence, pathoge-nesis and management. Drug Saf 1999; 20:437-449.
4. Vaziri ND, Bai Y, Ni Z, Quiroz Y, Pandian R, Rodrigu-ez-Iturbe B. Intra-renal angiotensin II/AT1 receptor, oxidative stress, infammation, and progressive injury in renal mass reduction. J Pharmacol Exp Ther 2007; 323:85-93.
5. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 2003; 42:1075-1081.
6. Scholey JW. Angiotensin II and the glomerulus: focus on diabetic kidney disease. Curr Hypertens Rep 2003; 5:172-180.
7. Burdmann EA, Andoh T F, Yu L, Bennett WM. Cyclos-porine nephrotoxicity. Semin Nephrol 2003; 23:465-476.
8. Shihab FS, Andoh TF, Tanner AM, Bennett WM. Sodi-um depletion enhances fbrosis and the expression of TGF-beta1 and matrix proteins in experimental chronic cyclosporine nephropathy. Am J Kidney Dis 1997; 30:71-81.
9. Roullet JB, Xue H, McCarron DA, Holcomb S, Bennett WM. Vascular mechanisms of cyclosporin-in- duced hypertension in the rat. J Clin Invest 1994; 93:2244-2250.
10. Mikkelsen EO, Poulsen SH, Nyborg NCB, Korsga-ard N, Sehested J. Difference between aortic and renal vascular reactivity in cyclosporin A treated rats and the effect of cicletanine. Naunyn-Schmiedeberg's archives of pharmacology 1992; 345:356-361.
11. Auch-Schwelk W, Bossaller C, Gotze S, Thelen J, Fleck E. Endothelial and vascular smooth muscle function after chronic treatment with cyclosporin A. J Cardiovasc Pharmacol 1993; 21:435-440.
12. Abdulla MH, Sattar MA, Abdullah NA, Khan MAH, Allah HHA, Johns EJ. Interaction between reninan-giotensin system and sympathetic nervous system in the systemic circulation of conscious Sprague-Dawley rats. HealthMed 2010; 2:328-334.
13. Vitor EV, Oseas MF, Luiz Carlos DA, Celso F. Adult spontaneously hypertensive rats from the same laboratory present different barorefex gain. HealthMed 2011; 5:258-264.
14. Amudha G, Josephine A, Mythili Y, Sundarapan-diyan R, Varalakshmi P. Therapeutic effcacy of DL-alpha-lipoic acid on cyclosporine A induced renal alterations. Eur J Pharmacol 2007; 571:209-214.
15. Abdulla MH, Sattar MA, Abdullah NA, Khan MA, Anand Swarup KR, Johns EJ. The contribution of alpha(1B)-adrenoceptor subtype in the renal vas-culature of fructose-fed Sprague-Dawley rats. Eur J Nutr 2010; 1-10.
16. Armenia A, Munavvar AS, Abdullah NA, Helmi A, Johns EJ. The contribution of adrenoceptor subtype(s) in the renal vasculature of diabetic spontaneously hypertensive rats. Br J Pharmacol 2004; 142:719-726.
17. Khan AH, Sattar MA, Abdullah NA, Johns EJ. In-fuence of cisplatin-induced renal failure on the alpha(1)-adrenoceptor subtype causing vasocon-striction in the kidney of the rat. Eur J Pharmacol 2007; 569:110-118.
18. Abdul Sattar M, Johns EJ. Alpha 1-adrenoceptor subtypes mediating adrenergic vasoconstriction in kidney, one-clip Goldblatt and deoxycorticosterone acetate-salt hypertensive rats. J Cardiovasc Pharmacol 1994; 24:420-428.
19. Hye Khan MA, Sattar MA, Abdullah NA, Johns EJ. Infuence of combined hypertension and renal failure on functional alpha(1)-adrenoceptor subtypes in the rat kidney. Br J Pharmacol 2008; 153:1232-1241.
20. Nishiyama A, Kobori H, Fukui T, Zhang GX, Yao L, Rahman M, Hitomi H, Kiyomoto H, Shokoji T, Ki-mura S, Kohno M, Abe Y. Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension. Hypertension 2003; 42:754-760.
21. Robertson JL. Chemically induced glomerular injury: a review of basic mechanisms and specifc xenobiotics. Toxicol Pathol 1998; 26:64-72.
22. Satyanarayana PSV, Chopra K. Oxidative stress-mediated renal dysfunction by cyclosporine A in rats: attenuation by trimetazidine. Ren Fail 2002; 24:259-274.
23. Wang C, Salahudeen AK, McClain M, Whitehead J. Lipid peroxidation accompanies cyclosporine nep-hrotoxicity: effects of vitamin E. Kidney Int 1995; 47:927-934.
24. Kon V, Sugiura M, Inagami T, Harvie BR, Ichikawa I, Hoover RL. Role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int 1990; 37:1487-1491.
25. Rosen S, Greenfeld Z, Brezis M. Chronic cyclospo-rine-induced nephropathy in the rat. A medullary ray and inner stripe injury. Transplantation 1990; 49:445-452.
26. Stroth U, Unger T. The renin-angiotensin system and its receptors. J Cardiovasc Pharmacol 1999; 33 Suppl 1:S21-28; discussion S41-23.
27. Curtis JJ, Luke RG, Jones P, Diethelm AG. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. The Am J Med 1988; 85:134-138.
28. Burton C, Harris K P. The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis 1996; 27:765-775.
29. Lieberthal W, Nigam SK. Acute renal failure. II. Experimental models of acute renal failure: imperfect but indispensable. Am J Physiol-Renal 2000; 47:F1-F12.
30. Shihab FS. Cyclosporine nephropathy: Pathophysiology and clinical impact. 1996; In, p 536.
31. Lim SW, Li C, Sun BK, Han KH, Kim WY, Oh YW, Lee JU, Kador PF, Knepper MA, Sands JM, Kim J, Yang CW. Long-term treatment with cyclospori-ne decreases aquaporins and urea transporters in the rat kidney. Am J Physiol Renal Physiol 2004; 287:F139-151.
32. Hostetter TH, Olson JL, Rennke HG, Venkatacha-lam MA, Brenner BM. Hyperfltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981; 241:F85-93.
33. Yoshida Y, Fogo A, Ichikawa I. Glomerular he-modynamic changes vs. hypertrophy in experimental glomerular sclerosis. Kidney Int 1989; 35:654-660.
34. Liu J, Albers MW, Wandless TJ, Luan S, Alberg DG, Belshaw PJ, Cohen P, MacKintosh C, Klee CB, Schreiber SL. Inhibition of T cell signaling by im-munophilin-ligand complexes correlates with lossof calcineurin phosphatase activity. Biochemistry 1992; 31:3896-3901.
35. Lassila M. Cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet. 2000; Available at: http:// ethesis.helsinki.f/julkaisut/laa/biola/vk/lassila/cyc-lospo.pdf.
36. Zimmerhackl LB, Fretschner M, Steinhausen M. Cyclosporin reduces renal blood fow through vaso-constriction of arcuate arteries in the hydronephro-tic rat model. J Mol Med 1990; 68:166-174.
37. Turrin MQ, Ferrari M, De Moraes S. Spontaneous and renal hypertensive rats: responsiveness of isolated right and left atria to noradrenaline, isopre-naline and methoxamine. J Auton Nerv Syst 1994; 46:1-8.
38. Nitta K, Friedman AL, Nicastri AD, Paik S, Friedman EA. Granular juxtaglomerular cell hyperpla-sia caused by cyclosporine. Transplantation 1987; 44:417-421
39. Fujii T, Sugiura T, Ohkita M, Kobuchi S, Takaoka M, Matsumura Y. Selective antagonism of the po-stsynaptic [alpha] 1-adrenoceptor is protective against ischemic acute renal failure in rats. Eur J Pharmacol 2007; 574:185-191.
40. Lyson T, Ermel LD, Belshaw PJ, Alberg DG, Schre-iber SL, Victor RG. Cyclosporine- and FK506-indu-ced sympathetic activation correlates with calcineu-rin-mediated inhibition of T-cell signaling. Circ Res 1993; 73:596-602.
41. Avdonin PV, Cottet-Maire F, Afanasjeva GV, Loktio-nova SA, Lhote P, Ruegg UT. Cyclosporine A up-re-gulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells. Kidney Int 1999; 55:2407-2414.
42. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000. 52:11-34.
43. Tavares P, Martinez-Salgado C, Ribeiro CA, Eleno N, Lopez-Novoa JM, Teixeira F. Cyclosporin Effect on Rat Aorta [alpha] 1-Adrenoceptors and Their Transduction Mechanisms. J Cardiovasc Pharm 2002; 40:181.
44. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106:1974-1979.